Safety and efficacy profile of belzutifan, a hypoxia-inducible factor-2a inhibitor, in patients with renal cell carcinoma: Meta-analysis and systematic review

Category Systematic review
JournalJ. Clin. Oncol.
Year 2024
This article has no abstract
Epistemonikos ID: 4d3769bb267b83f795c2e85389d54ff9eb3f4970
First added on: Aug 14, 2024